Your browser doesn't support javascript.
loading
Effect of dose of behavioral weight loss treatment on glycemic control in adults with prediabetes.
Bauman, Viviana; Ariel-Donges, Aviva H; Gordon, Eliza L; Daniels, Michael J; Xu, Dandan; Ross, Kathryn M; Limacher, Marian C; Perri, Michael G.
Afiliação
  • Bauman V; Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
  • Ariel-Donges AH; Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
  • Gordon EL; Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
  • Daniels MJ; Department of Statistics, University of Florida, Gainesville, Florida, USA.
  • Xu D; Department of Statistics and Data Sciences, University of Texas at Austin, Austin, Texas, USA.
  • Ross KM; Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
  • Limacher MC; Department of Medicine, University of Florida, Gainesville, Florida, USA.
  • Perri MG; Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
BMJ Open Diabetes Res Care ; 7(1): e000653, 2019.
Article em En | MEDLINE | ID: mdl-31245006
ABSTRACT

Objective:

This study examined the effects of three doses of behavioral weight loss treatment, compared with a nutrition education control group, on changes in glycemic control in individuals with obesity and prediabetes. Research design and

methods:

The study included 287 adults (77% female, 81% White; mean (SD) age=54.1 (10.5) years, body mass index=36.3 (3.9) kg/m2, and hemoglobin A1c (HbA1c)=5.9 (0.2%)). Participants were randomized to one of three behavioral treatment doses (high=24 sessions, moderate=16 sessions, or low=8 sessions) or to an education group (control=8 sessions). Changes in HbA1c, fasting glucose, and body weight were assessed from baseline to 6 months.

Results:

Mean (99.2% credible interval (CI)) reductions in HbA1c were 0.11% (0.07% to 0.16%), 0.08% (0.03% to 0.13%), 0.03% (-0.01% to 0.07%), and 0.02% (-0.02% to 0.07%), for the high, moderate, low, and control conditions, respectively. Mean (CI) reductions in fasting blood glucose were 0.26 mmol/L (0.14 to 0.39), 0.09 mmol/L (0 to 0.19), 0.01 mmol/L (-0.07 to 0.09), and 0.04 mmol/L (-0.03 to 0.12) for the high, moderate, low, and control conditions, respectively. The high-dose treatment produced significantly greater reductions in HbA1c and fasting blood glucose than the low-dose and control conditions (posterior probabilities (pp)<0.001); no other significant between-group differences were observed. Mean (CI) reductions in body weight were 10.91 kg (9.30 to 12.64), 10.08 kg (8.38 to 11.72), 6.35 kg (5.19 to 7.69), and 3.82 kg (3.04 to 4.54) for the high, moderate, low, and control conditions, respectively. All between-group differences in 6-month weight change were significant (pps<0.001) except for the high-dose versus moderate-dose comparison.

Conclusion:

For adults with obesity and prediabetes a high dose of behavioral treatment involving 24 sessions over 6 months may be needed to optimize improvements in glycemic control. Trial registration number NCT00912652.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Pré-Diabético / Terapia Comportamental / Biomarcadores / Redução de Peso / Índice de Massa Corporal / Diabetes Mellitus Tipo 2 / Obesidade Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMJ Open Diabetes Res Care Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Pré-Diabético / Terapia Comportamental / Biomarcadores / Redução de Peso / Índice de Massa Corporal / Diabetes Mellitus Tipo 2 / Obesidade Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMJ Open Diabetes Res Care Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos